Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07662044 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Not yet
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT07662044 is a Phase 3 study that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 800 participants.
The verdict
NCT07662044, a Phase 3 study, has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Interventions
- DRUG Dapagliflozin
- DRUG Elecoglipron
- DRUG Elecoglipron-matched placebo
- DRUG Dapagliflozin-matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2026-07-06 |
| Est. Completion | 2028-07-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07662044
The ClinicalTrials.gov registry entry for NCT07662044 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dapagliflozin is the first listed.
NCT07662044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07662044 about?
NCT07662044 is a clinical study titled "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucos...
What is the current status of trial NCT07662044?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2026-07-06. Estimated completion is 2028-07-14.
What interventions are being tested in trial NCT07662044?
The interventions under investigation include: Dapagliflozin (DRUG), Elecoglipron (DRUG), Elecoglipron-matched placebo (DRUG), Dapagliflozin-matched placebo (DRUG).
Who is sponsoring clinical trial NCT07662044?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.